Bifogade filer
Cantargia presents new results at EADV 2024 highlighting the potential of CAN10 treatment in dermatology
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today presented data from preclinical experiments showing the high potential of the IL1RAP targeting antibody CAN10 in treatment of dermatological diseases. The results show overexpression of IL1RAP in a number cell types in hidradenitis suppurativa (HS) and psoriasis skin lesions. The treatment effect of CAN10 in models of skin inflammation was potent and superior to IL-1β blockade. The results are presented at the EADV congress Sep 25-28 in Amsterdam.
“We are intrigued by the opportunities of CAN10 in treatment of a number of skin diseases. The broad mechanism of action of CAN10 seem well suited for this huge disease segment and preparations are ongoing for the first phase 2 study in HS planned to start 2025” said Göran Forsberg, CEO of Cantargia.
The CAN10 antibody targeting IL1RAP has a broad and potent mechanism of action by potently blocking the activity of IL-1, IL-33 and IL-36. Phase 1 clinical trial is ongoing ahead of the first phase 2 trial planned to start H2 2025. The results presented at EADV show that skin from patients with inflammatory skin diseases such as HS and psoriasis have increased IL1RAP expression on immune cells, fibroblasts and endothelial cells. In mouse models of skin and joint inflammation, CAN10 surrogate antibody reduce tissue inflammation and systemic levels of IL-17. These effects are more potent than blocking IL-1β only. CAN10 also counteracts fibrosis induced by a cocktail of IL-1, IL-33 and IL-36.
The poster is presented at the EADV Congress 2024 in Amsterdam on Sep 25-28 by Dr Sara Rattik and Dr David Liberg from Cantargia. The poster will be uploaded on Cantargia’s webpage www.cantargia.com.